Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GSK acquiring Reliant for $1.7B

GlaxoSmithKline (LSE:GSK; GSK) said it will acquire cardiovascular company Reliant (Liberty Corner, N.J.) for $1.7 billion in cash. The acquisition gives GSK

Read the full 225 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE